Clareo Health | Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer
Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Netherlands Cancer Institute
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. signed and written informed consent
2. age ≥ 18 years
3. patients eligible for interval cytoreductive surgery
1. histological proven FIGO stage III primary high grade serous ovarian, fallopian tube, or extra-ovarian cancer
2. when only cytology is performed to confirm the diagnosis ovarian carcinoma, immunohistochemistry should be performed including keratin 7, keratin 20, p53, PAX8
3. neo-adjuvant chemotherapy consists of (at least) 3 courses of carboplatin/paclitaxel
4. following 2 cycles of chemotherapy no progression should occur
4. treated with optimal or complete interval cytoreductive surgery
5. fit for major surgery, WHO performance status 0-2
6. adequate bone marrow function (hemoglobin level \>5.5 mmol/L; leukocytes \>3 x 109/L; platelets \>100 x 109 /L)
7. adequate hepatic function (ALT, AST and bilirubin \<2.5 times upper limit of normal)
8. adequate renal function (creatinine clearance ≥ 60 ml/min using Cockcroft-Gault formula or 24-hour measurement or ml/min/1,73 m2 using MDRD or CKD-EPI)
9. able to understand the patient information
You may not be if
1. history of previous malignancy treated with chemotherapy
